Ngā hua rapu - Scott Gettinger

Whakamahine hua
  1. 1
    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? mā Scott Gettinger, Katerina Politi

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Oncolytic virus immunotherapy: future prospects for oncology

    Oncolytic virus immunotherapy: future prospects for oncology mā Junaid Raja, Johannes Ludwig, Scott Gettinger, Kurt A. Schalper, Hyun S. Kim

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer mā Kavita M. Dhodapkar, Scott Gettinger, Rituparna Das, Henry Zebroski, Madhav V. Dhodapkar

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial mā Ruth McCorkle, Sangchoon Jeon, Elizabeth Ercolano, Mark Lazenby, Amanda Reid, Marianne Davies, Diane Viveiros, Scott Gettinger

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy mā Jing W. Hughes, Nalini Vudattu, Mario Sznol, Scott Gettinger, Harriet M. Kluger, Beatrice Lupsa, Kevan C. Herold

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy mā Veronica Shi, Nemanja Rodić, Scott Gettinger, Jonathan S. Leventhal, Julia P. Neckman, Michael Girardi, Marcus Bosenberg, Jennifer Choi

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) mā Daniel E. Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott Gettinger, Roy S. Herbst, David L. Rimm, Kurt A. Schalper

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer mā Johannes Uhlig, Meaghan Dendy Case, Justin D. Blasberg, Daniel J. Boffa, Anne C. Chiang, Scott Gettinger, Hyun S. Kim

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling mā Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer mā Gregory A. Otterson, Miguel A. Villalona‐Calero, William J. Hicks, Xueliang Pan, John Ellerton, Scott Gettinger, John R. Murren

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy mā Kathleen C. Suozzi, Maximilian Stahl, Christine J. Ko, Anne C. Chiang, Scott Gettinger, Mark D. Siegel, Christopher G. Bunick

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy mā Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Treatment of Stage IV Non-small Cell Lung Cancer

    Treatment of Stage IV Non-small Cell Lung Cancer mā Mark A. Socinski, Tracey L. Evans, Scott Gettinger, Thomas A. Hensing, Lecia VanDam Sequist, Belinda Ireland, Thomas E. Stinchcombe

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Immune Checkpoint Inhibitor–Associated Pericarditis

    Immune Checkpoint Inhibitor–Associated Pericarditis mā Mehmet Altan, Maria Toki, Scott Gettinger, Daniel E. Carvajal-Hausdorf, Jon Zugazagoitia, John H. Sinard, Roy S. Herbst, David L. Rimm

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma mā Guoping Cai, Rebecca A. Wong, David C. Chhieng, Gillian H. Levy, Scott Gettinger, Roy S. Herbst, Jonathan Puchalski, Robert Homer, Pei Hui

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas mā Vamsidhar Velcheti, Kurt A. Schalper, Xiaopan Yao, Huan Cheng, Mehmet H. Kocoglu, Kavita M. Dhodapkar, Yanhong Deng, Scott Gettinger, David L. Rimm

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Programmed death ligand-1 expression in non-small cell lung cancer

    Programmed death ligand-1 expression in non-small cell lung cancer mā Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal, Valsamo Anagnostou, Konstantinos N. Syrigos, Mario Sznol, Roy S. Herbst, Scott Gettinger, Lieping Chen, David L. Rimm

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing

    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing mā Azeet Narayan, Nicholas Carriero, Scott Gettinger, Jeannie Kluytenaar, Kevin R. Kozak, Torunn I. Yock, Nicole E. Muscato, Pedro Ugarelli, Roy H. Decker, Abhijit A. Patel

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer

    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer mā Kimberly L. Johung, Xiaopan Yao, Fangyong Li, James B. Yu, Scott Gettinger, Sarah B. Goldberg, Roy H. Decker, Judith Hess, Veronica Chiang, Joseph N. Contessa

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors

    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors mā Y. Y. Janjigian, Egbert F. Smit, Leora Horn, Harry J.M. Groen, D. Ross Camidge, Scott Gettinger, Yali Fu, L. Denis, V.A. Miller, William Pao

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: